Article
Cardiac & Cardiovascular Systems
Saloni Kapoor, Jianhui Zhu, Arman Kilic, Catalin Toma, Ibrahim Sultan, Floyd Thoma, Conrad Smith, Oscar C. Marroquin, Forozan Navid, Joon S. Lee, Suresh R. Mulukutla
Summary: This study reports outcomes stratified by surgical risk after PCI or CABG in patients with multivessel coronary disease. The study found that for low-risk patients, the mortality rate after CABG was 10.9%, and after PCI it was 21.6%. For intermediate-high risk patients, the mortality rate after CABG was 40.1%, and after PCI it was 61.8%.
ANNALS OF THORACIC SURGERY
(2022)
Article
Endocrinology & Metabolism
Hiddo J. L. Heerspink, Priya Vart, Niels Jongs, Brendon L. Neuen, George Bakris, Brian Claggett, Muthiah Vaduganathan, Finnian McCausland, Kieran F. Docherty, Pardeep S. Jhund, Scott D. Solomon, Vlado Perkovic, John J. V. McMurray
Summary: The combination treatment of SGLT2 inhibitors and MRA in patients with type 2 diabetes and CKD can significantly extend event-free survival and overall survival, with an estimated gain of 6.7 years in event-free survival compared to ACE inhibitors/angiotensin receptor blockers. This conclusion is supported by both trial data and observational study results. Even in a conservative scenario, the combination therapy still provides a substantial gain of 2.5 years in event-free survival.
DIABETES OBESITY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Jonathan Mui, Jiandong Zhou, Sharen Lee, Keith Sai Kit Leung, Teddy Tai Loy Lee, Oscar Hou In Chou, Shek Long Tsang, Abraham Ka Chung Wai, Tong Liu, Wing Tak Wong, Carlin Chang, Gary Tse, Qingpeng Zhang
Summary: The study found that compared to DPP4I users, SGLT2I users had lower incidences of dementia, Parkinson's disease, and cerebrovascular mortality.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Javed Butler, Milton Packer, Tariq Jamal Siddiqi, Michael Boehm, Martina Brueckmann, James L. Januzzi, Subodh Verma, Ingrid Gergei, Tomoko Iwata, Christoph Wanner, Joao Pedro Ferreira, Stuart J. Pocock, Gerasimos Filippatos, Stefan D. Anker, Faiez Zannad
Summary: This study aimed to evaluate the effect of empagliflozin on patients with chronic kidney disease. It was found through a pooled analysis of EMPEROR-Reduced and EMPEROR-Preserved that empagliflozin can reduce the risk of heart failure and heart failure-related death in patients with different risk categories.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Martina Belli, Lucy Barone, Alfonso Bellia, Domenico Sergi, Dalgisio Lecis, Francesca Romana Prandi, Marialucia Milite, Chiara Galluccio, Saverio Muscoli, Francesco Romeo, Francesco Barilla
Summary: Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome, and its incidence is increasing due to an ageing population and the increasing incidence of various diseases. The complexity of HFpEF has made it difficult to identify specific therapies, although some antidiabetic drugs have shown positive effects. There is limited evidence regarding the potential benefits of combined therapy with SGLT2-Is and GLP-1 RAs in HFpEF patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Hiddo J. L. Heerspink, C. David Sjostrom, Niels Jongs, Glenn M. Chertow, Mikhail Kosiborod, Fan Fan Hou, John J. McMurray, Peter Rossing, Ricardo Correa-Rotter, Raisa Kurlyandskaya, Bergur Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler
Summary: Dapagliflozin significantly reduces all-cause mortality in CKD patients, predominantly by reducing non-cardiovascular deaths. The benefits are consistent across pre-specified subgroups and driven largely by reductions in deaths due to infections and malignancies.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Gilles Rioufol, Francois Derimay, Francois Roubille, Thibault Perret, Pascal Motreff, Denis Angoulvant, Yves Cottin, Ludovic Meunier, Laura Cetran, Guillaume Cayla, Brahim Harbaoui, Jean-Yves Wiedemann, Eric Van Belle, Christophe Pouillot, Nathalie Noirclerc, Jean-Francois Morelle, Francois-Xavier Soto, Christophe Caussin, Bernard Bertrand, Thierry Lefevre, Patrick Dupouy, Pierre-Francois Lesault, Franck Albert, Olivier Barthelemy, Rene Koning, Laurent Leborgne, Pierre Barnay, Philippe Chapon, Sebastien Armero, Antoine Lafont, Christophe Piot, Camille Amaz, Bernadette Vaz, Lakhdar Benyahya, Yvonne Varillon, Michel Ovize, Nathan Mewton, Gerard Finet
Summary: The FUTURE trial investigated whether a treatment strategy based on FFR was superior to a traditional strategy in the treatment of multivessel CAD, and found no significant difference in rates of major adverse cardiac events or death at 1-year follow-up between the two groups.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Review
Endocrinology & Metabolism
Andre J. Scheen, Pierre Delanaye
Summary: RAAS blockers and SGLT2 inhibitors have shown nephroprotective effects and a reduced risk of acute kidney injury in patients with type 2 diabetes. Both prospective trials and retrospective observational studies support these findings.
DIABETES & METABOLISM
(2022)
Article
Cardiac & Cardiovascular Systems
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro
Summary: This study compared the cardiovascular risk differences among individual sodium-glucose cotransporter-2 (SGLT2) inhibitors used for the treatment of diabetes mellitus (DM). The results showed no significant differences in the risks of developing heart failure, myocardial infarction, angina pectoris, stroke, and atrial fibrillation among different SGLT2 inhibitors.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Endocrinology & Metabolism
Victor Okunrintemi, Basem M. Mishriky, James R. Powell, Doyle M. Cummings
Summary: SGLT2 inhibitors significantly lower the risk of incident atrial fibrillation in high-risk individuals, regardless of diabetes status. However, further research is needed to evaluate its clinical significance.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Philip C. M. Au, Kathryn C. B. Tan, Bernard M. Y. Cheung, Ian C. K. Wong, Ying Wong, Ching-Lung Cheung
Summary: Analysis of data on the use of SGLT2 inhibitors and DPP4is in diabetic patients revealed that SGLT2 inhibitors were associated with a lower risk of pneumonia and pneumonia mortality.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Biochemistry & Molecular Biology
Roko Skrabic, Marko Kumric, Josip Vrdoljak, Doris Rusic, Ivna Skrabic, Marino Vilovic, Dinko Martinovic, Vid Duplancic, Tina Ticinovic Kurir, Josko Bozic
Summary: SGLT2i have shown beneficial renoprotective effects in CKD, but further research is needed to determine their effectiveness in different patient subgroups.
Article
Endocrinology & Metabolism
Michael Fralick, Michael Colacci, Deva Thiruchelvam, Tara Gomes, Donald A. Redelmeier
Summary: The study showed that older adults prescribed an SGLT2 inhibitor had lower rates of heart failure hospitalization and mortality, lower rates of hypoglycemia, but higher rates of diabetic ketoacidosis compared to those prescribed a DPP-4 inhibitor.
DIABETES OBESITY & METABOLISM
(2021)
Article
Medicine, General & Internal
Etienne Puymirat, Guillaume Cayla, Tabassome Simon, Philippe G. Steg, Gilles Montalescot, Isabelle Durand-Zaleski, Alicia le Bras, Romain Gallet, Khalife Khalife, Jean-Francois Morelle, Pascal Motreff, Gilles Lemesle, Jean-Guillaume Dillinger, Thibault Lhermusier, Johanne Silvain, Vincent Roule, Jean-Noel Labeque, Gregoire Range, Gregory Ducrocq, Yves Cottin, Didier Blanchard, Anais Charles Nelson, Bernard De Bruyne, Gilles Chatellier, Nicolas Danchin
Summary: In patients with STEMI undergoing complete revascularization, an FFR-guided strategy did not have a significant benefit over an angiography-guided strategy with respect to the risk of death, myocardial infarction, or urgent revascularization at 1 year. However, the findings do not allow for a conclusive interpretation due to wide confidence intervals.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Endocrinology & Metabolism
Wei-Syun Hu, Cheng-Li Lin
Summary: By analyzing nationwide data in Taiwan, this study aimed to determine the association between type 2 diabetes mellitus (T2DM) patients with and without the use of sodium-glucose cotransporter-2 inhibitors (SGLT2I) and the occurrence of cataracts. The hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated using a Cox proportional hazards regression model, with adjustment for various risk factors. The results showed that T2DM patients using SGLT2I had a 2.04-fold increased risk of cataract compared to those without SGLT2I, after adjusting for sex, age, comorbidities, and medications.
ACTA DIABETOLOGICA
(2023)